8-K: Silo Pharma Amends License Agreement with University of Maryland, Baltimore, Revising Development Milestones

Silo Pharma has amended its Master License Agreement with the University of Maryland, Baltimore, updating the schedule of diligence milestones for licensed product development.

Summary

• Silo Pharma's subsidiary has entered into a Fourth Amendment to its Master License Agreement with the University of Maryland, Baltimore.
• This amendment revises the schedule of diligence milestones for the development of licensed products.
• The original Master License Agreement was effective as of February 12, 2021.
• The Fourth Amendment replaces the previous Schedule C with a new schedule of milestones.
• All other terms and conditions of the original agreement remain in effect.

Sentiment

Score: 7

Explanation: The document outlines a positive step in the development process with clear milestones, but the long timeline and potential risks temper the overall sentiment.

Positives

• The amendment provides a clear timeline for the development of licensed products.
• The revised milestones offer a structured approach to product development.
• The agreement maintains the original royalty rate and payment obligations.

Risks

• Failure to meet the revised milestones could impact the development timeline and the agreement.
• The commercialization plan is subject to University approval, which could lead to delays or changes.
• The milestones are dependent on successful completion of various studies and regulatory approvals.

Future Outlook

The agreement outlines a clear path for the development and commercialization of licensed products, with specific milestones to be achieved over the next decade.

Management Comments

• Eric Weisblum, Chief Executive Officer, signed the agreement on behalf of Silo Pharma.

Industry Context

This type of agreement is common in the pharmaceutical industry, where companies license technology from universities to develop new products. The revised milestones reflect the typical stages of drug development, from preclinical studies to commercialization.

Comparison to Industry Standards

• The milestones outlined in the agreement are consistent with industry standards for drug development timelines.
• The timelines for completing preclinical studies, clinical trials, and regulatory filings are comparable to those of other pharmaceutical companies developing similar products.
• The agreement's structure, including royalty rates and payment obligations, is typical for licensing agreements between universities and pharmaceutical companies.

Stakeholder Impact

• Shareholders will be interested in the progress of the licensed product development.
• The agreement provides a framework for future revenue generation.
• The company's employees will be involved in the execution of the milestones.

Next Steps

• Silo Pharma will need to complete the in vitro peptide binding study by March 30, 2025.
• Silo Pharma will need to complete preclinical safety and efficacy studies by September 30, 2025.
• Silo Pharma will need to deliver a revised Commercialization Plan by December 31, 2025.
• Silo Pharma will need to complete GMP production and animal testing by February 12, 2027.
• Silo Pharma will need to file an IND by February 12, 2028.
• Silo Pharma will need to dose the first patient in a Phase 1 clinical trial by February 12, 2029.
• Silo Pharma will need to dose the first patient in a Phase 2 clinical trial by February 12, 2030.
• Silo Pharma will need to file an NDA by February 12, 2033.
• Silo Pharma will need to achieve the first commercial sale of a licensed product by February 12, 2034.

Key Dates

Keywords

License Agreement, Diligence Milestones, Pharmaceutical Development, Clinical Trials, Regulatory Approval, Commercialization, Silo Pharma, University of Maryland